ReviewMolecular cancer2024
Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications.
Review in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- [Advancement in the role of exosomes for hepatitis B virus infection diagnosis and treatment: mechanisms and clinical applications].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer.Cancer gene therapy · 2026Review
- Role of mesenchymal stem cells and their derived exosomes in cervical cancer: Bidirectional mechanisms and research progress (Review).Oncology letters · 2026Review
- TIM-3, a potential target for sepsis therapy.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Review
- A macrophage MHC-I axis links intratumoral heterogeneity to terminal CD8NPJ precision oncology · 2026Article
- Construction of a homologous targeting exosome-based drug delivery system for colorectal cancer and evaluation of its anti-tumor efficacy.Scientific reports · 2026Article
- NK-cell-derived exosomes exert antitumor potency via miR-140/XYLT1/HSPG2 axis.Cellular & molecular biology letters · 2026Article
- Origin dictates function: The dual roles of exosomes derived from diverse origins in the onset and progression of colorectal cancer (Review).Oncology reports · 2026Review
- NIR-II Nanomedicine Engineered CAR-NK Cells for Precision Navigation and Potentiating Lung Cancer Immunotherapy by Remodeling Tumor Microenvironment.Journal of the American Chemical Society · 2026Article
- MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation.Journal of nanobiotechnology · 2026Article
- Extracellular vesicles in colorectal cancer: immunomodulation, diagnostics, and therapeutic perspectives.Medical oncology (Northwood, London, England) · 2026Review
- Bench-to-Bedside Insights into the Challenges of Immunosuppression in Sepsis.Pathogens (Basel, Switzerland) · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.Breast cancer (Dove Medical Press) · 2026Review
- Microneedle-Enabled Exosome Therapy: From Tumor Targeting to Precision Treatment of Complex Diseases.International journal of nanomedicine · 2026Review
- Exosome-Inspired Nanocarriers in Cancer Therapy: Bio-Derived Nanotechnology Meets Nano Drug Delivery.International journal of nanomedicine · 2026Review
- Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
- A Machine Learning Model Based on Clinical Factors to Predict the Efficacy of First-Line Immunochemotherapy for Patients With Advanced Gastric Cancer: Retrospective Study.JMIR medical informatics · 2025Article
- Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are important immune cells in the organism and are the third major type of lymphocytes besides T cells and B cells, which play an important function in cancer therapy. In addition to retaining the tumor cell killing function of natural killer cells, natural killer cell-derived exosomes cells also have the characteristics of high safety, wide source, easy to preserve and transport. At the same time, natural killer cell-derived exosomes are easy to modify, and the engineered exosomes can be used in combination with a variety of current cancer therapies, which not only enhances the therapeutic efficacy, but also significantly reduces the side effects. Therefore, this review summarizes the source, isolation and modification strategies of natural killer cell-derived exosomes and the combined application of natural killer cell-derived engineered exosomes with other antitumor therapies, which is expected to accelerate the clinical translation process of natural killer cell-derived engineered exosomes in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.